Clinical Trials Logo

Filter by:
NCT ID: NCT06406543 Active, not recruiting - Clinical trials for Vitamin D Deficiency

Vitamin D in Armenia: Vitamin D Repletion Strategies With Dibase, and Vitamin D and Vitamin D Binding Protein and COVID

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

This is a three-arm unblinded prospective interventional study of vitamin D supplementation in participants with insufficient vitamin D at three different induction and maintenance dosing regimens (high dose, low frequency; medium dose, medium frequency, and low dose, high frequency). Measurements of serum vitamin D will take place at 4, 8, 12, 24, and 36 weeks, and will be compared to determine which regimen was most effective at achieving and maintaining ideal serum vitamin D levels.

NCT ID: NCT06322108 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

Start date: May 2024
Phase: Phase 2
Study type: Interventional

The goal of this study is to see if the combination of immunotherapy agents botensilimab and balstilimab is safe and effective in participants with metastatic non-small cell lung cancer (NSCLC) as a first-line treatment.

NCT ID: NCT06217393 Recruiting - Clinical trials for Functional Dyspepsia

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Start date: February 28, 2024
Phase: Phase 3
Study type: Interventional

The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to: - assess whether the dose of Itopride Hydrochloride 150 mg extended release tablets, taken once daily has a similar effect on gastrointestinal symptoms caused by gastric dysmotility and delayed gastric emptying, like bloating sensation, early satiety, postprandial fullness, upper abdominal pain or discomfort, anorexia, heartburn, nausea and vomiting in functional (non-ulcer) dyspepsia or chronic gastritis, as Itopride Hydrochloride 50 mg film coated tablets administered thrice a day. - investigate assessment of the treatment provided to each participant. - monitor safety and tolerability of Itopride Hydrochloride 150 mg extended release tablets, taken once daily before one of the main meals (preferably same meal throughout the treatment) and Itopride Hydrochloride 50 mg film coated tablets thrice daily before meals.

NCT ID: NCT06061718 Active, not recruiting - Ocular Hypertension Clinical Trials

Travoprost Intraocular Implant in Conjunction With Cataract Surgery

Start date: September 11, 2023
Phase: Phase 3
Study type: Interventional

Subjects with cataract requiring extraction and who have open-angle glaucoma or ocular hypertension will undergo screening and washout from IOP-lowering medication, if applicable. Eligible subjects who meet all inclusion criteria and none of the exclusion criteria and who undergo successful cataract extraction with implantation of a posterior chamber intraocular lens (PC-IOL) will receive a travoprost intraocular implant and followed up for 12 months.

NCT ID: NCT06048003 Recruiting - Clinical trials for ST Elevation Myocardial Infarction

Armenian National Registry of Myocardial Infarction

ARMI
Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

This is a national, multicenter prospective observational study of patients presenting to hospitals in Armenia with STEMI diagnosis. The main questions it aims to answer are: - Determine the rate of in-hospital mortality for the patients with STEMI admitted to the participating hospitals. - Compare short and long-term CV and all-cause mortality and hospitalization. - Determine how professional guidelines are followed in real-world situations.

NCT ID: NCT05935189 Recruiting - Clinical trials for Hepatocellular Carcinoma

Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens

TIR-HCC
Start date: July 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of the study is to establish a cancer registry to facilitate research and assist in the identification of additional risk factors for hepatocellular carcinoma. The main objectives are: 1. provide a mechanism to store the information about subjects with hepatocellular carcinoma 2. use of tissue samples for translational/further research purposes

NCT ID: NCT05916586 Recruiting - Acute Heart Failure Clinical Trials

Effect of Short-term Prednisone Therapy on C-reactive Protein in Patients With Acute Heart Failure

CORTAHF
Start date: August 11, 2023
Phase: N/A
Study type: Interventional

This is a multicenter, parallel-group, randomized, open-label, controlled trial. Patients with a diagnosis of acute heart failure (AHF) in the emergency department (ED) or after emergency presentation to hospital will be screened and informed of the study. After signed consent, patients will be randomized into the control group (usual AHF treatment) or intervention group (usual AHF treatment + prednisone). Prednisone will be given for 7 days. Patients will be assessed at days 2, 4 or at discharge if earlier, and at day 7 at hospital visit. If the patient has been discharged before day 7, a follow-up visit will be scheduled at day 7 for endpoints assessment followed by a scheduled hospital visit at day 31 and a telephone follow-up at day 91. Study drug will be dispensed for the patient to take home until day 7.

NCT ID: NCT05904301 Recruiting - Clinical trials for Rheumatoid Arthritis

Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases

NAREG
Start date: June 21, 2023
Phase:
Study type: Observational

Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.

NCT ID: NCT05891821 Recruiting - Lymphoma Clinical Trials

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

The goal of this study is to see if the drug balstilimab is safe and effective in participants with relapsed/refractory lymphomas. Participants will receive balstilimab every 3 weeks and their outcomes will be assessed periodically.

NCT ID: NCT05876754 Recruiting - Cholangiocarcinoma Clinical Trials

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

ProvIDHe
Start date: May 3, 2023
Phase: Phase 3
Study type: Interventional

A Phase 3b research study to consolidate the data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma (CCA). All patients who meet inclusion criteria will be enrolled to receive ivosidenib tablets orally once daily for 28 day cycles, continuing as long as clinical benefit and consent for participation is maintained. There will be a minimum of 6 study visits from screening until the final follow-up, if one cycle of treatment is completed and consent is maintained through 18 months of follow-up. Each additional cycle completed will add one study visit, on the first day of each cycle.